Ovid Therapeutics (OVID) EV to EBITDA (2017 - 2026)

Ovid Therapeutics (OVID) has reported EV to EBITDA for 10 consecutive years, with 24.19 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EV to EBITDA fell 924.74% year-over-year to 24.19; the trailing twelve-month figure through Jun 2026 stood at 6.51 (down 1917.91% YoY), and the FY2025 full-year result was 1.19, down 468.65% from the prior year.
• EV to EBITDA declined to 24.19 in Q2 2026 per OVID's latest filing, from 8.22 in the prior quarter.
• Across five years, EV to EBITDA topped out at 2.93 in Q2 2025 and bottomed at 24.19 in Q2 2026.
• Historically, EV to EBITDA has averaged 4.71 across 5 years, with a median of 3.67 in 2022.
• The sharpest annual moves came in 2023 and 2025: EV to EBITDA tumbled 14239.6% in 2023, then soared 169.57% in 2025.
• Over 5 years, EV to EBITDA stood at 0.17 in 2022, then plunged by 3843.63% to 6.7 in 2023, then jumped by 81.94% to 1.21 in 2024, then sank by 240.13% to 4.11 in 2025, then slumped by 488.26% to 24.19 in 2026.
• According to Business Quant data, EV to EBITDA over the past three periods registered 24.19, 8.22, and 4.11 for Q2 2026, Q1 2026, and Q4 2025 respectively.